|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **RNAi1** | **Drug2** | **Heat3 shock**  **(35°C)** | **Cytosolic4**  **(%)** | **Intermediate5 /nuclear (%)** | **N6** |
| Control | None | - | 92.6 | 7.4 | 27 |
| Control | None | + | 16.7 | 83.3 | 24 |
| *acn-1* | None | - | 87 | 13 | 30 |
| *acn-1* | None | + | 14 | 86 | 43 |
| *daf-2* | None | - | 15.6 | 84.4 | 45 |
| Control+ *daf-2* | None | - | 17.9 | 82.1 | 39 |
| *acn-1*+*daf-2* | None | - | 12 | 88 | 25 |
| None | Captopril (2.54 mM) | - | 95.2 | 4.7 | 21 |
| Control | Captopril (2.54 mM) | - | 94.1 | 5.8 | 17 |
| *daf-2* | Captopril (2.54 mM) | - | 10 | 90 | 30 |

**S1 Table *acn-1* RNAi and Captopril treatment did not cause substantial nuclear localization of DAF-16::GFP**